NCT00908024 - Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Colorectal CancerHead and Neck CancerNeoplasm Metastasis

Interventions

DRUG

BMS-754807

Tablets, Oral, doses vary during dose escalation, once daily, varies - treatment is continued to disease progression or MD/subject/sponsor decision

DRUG

cetuximab (Erbitux®)

IV infusion, IV, 400 mg/m² loading dose, then 250 mg/m², weekly, varies - treatment is continued to disease progression or MD/subject/sponsor decision

Trial Locations (5)

27710

Duke University Medical Center, Durham

53705

University Of Wisconsin, Madison

68114

Nebraska Methodist Hospital, Omaha

V5Z 4E6

Local Institution, Vancouver

M5G 2M9

Local Institution, Toronto